ArticleAnnals of medicine and surgery (2012)2025
Clinical trial landscape for stem cells in autoimmune and inflammatory diseases: a comprehensive analysis and path forward.
Article in Annals of medicine and surgery (2012), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autoimmune and inflammatory diseases present significant therapeutic challenges due to their chronic nature and limited response to conventional treatments. Stem cell-based therapies have emerged as a promising approach, leveraging their immunomodulatory and regenerative properties to address treatment-resistant cases. Methods: We conducted a comprehensive analysis of 1136 stem cell clinical trials from the TrialTrove database (October 2024), focusing on therapeutic efficacy, trial progression patterns, and geographic distribution. Key clinical outcomes and safety profiles were systematically evaluated. A choropleth map (Figure 1C) summarizes national activity across continents, with darker shading indicating more trials. Results: Stem cell trials showed substantial growth over two decades, increasing from 11 trials annually (2000-2004) to a peak of 73 trials in 2019. However, translation to late-phase studies remains limited, with only 10.2% of trials advancing to Phase III. Notable therapeutic successes include a 92.5% survival rate in systemic lupus erythematosus using umbilical cord mesenchymal stem cells and a 56.3% remission rate in Crohn's disease with adipose-derived mesenchymal stem cells versus 38.6% with placebo ( Conclusions: Stem cell-based therapies demonstrate significant therapeutic potential for autoimmune and inflammatory diseases. To accelerate clinical translation, the field must address standardization challenges, enhance late-phase trial development, and establish robust regulatory frameworks. These efforts are essential for realizing the full therapeutic potential of stem cell therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.